Orpha Labs AG Announces the Initiation of a Phase III Trial Ev...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BAAR, Switzerland, Feb 23, 2022, /PRNewswire-AsiaNet/-- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III trial with ORL-101 in patients with Leukocyte Adhesion Deficiency Type II (“LAD-II”). Orpha Labs AG is ...
Authors: LATEST ASIANET NEWS RELEASES